Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
category guide

Metabolic / Dual GLP-1/Glucagon Agonist Research Peptides Guide

In-depth research guide covering 3 peptides in the Metabolic / Dual GLP-1/Glucagon Agonist category. Includes evidence ratings, mechanisms, and clinical status for each compound.

Overview

This guide covers 3 research peptides in the Metabolic / Dual GLP-1/Glucagon Agonist category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.

Mazdutide — Phase I–II Clinical Trials

Evidence: C | Status: Approved in China (June 2024) for chronic weight management. Phase III in China for T2D. Not yet approved outside China.

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW ~4233.7 g/mol).

Use cases: Weight Management, Metabolic Health

Retatrutide 20mg
In Stock

Retatrutide 20mg

20mg

$99 USD
BPC-157 5mg
In Stock

BPC-157 5mg

5mg

$34 USD
Ipamorelin 10mg
In Stock

Ipamorelin 10mg

10mg

$49 USD

Pemvidutide — Phase I–II Clinical Trials

Evidence: C | Status: Phase II completed (MOMENTUM for obesity, IMPACT for NASH/MASH). Phase III anticipated.

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist being developed by Altimmune for the treatment of obesity and nonalcoholic steatohepatitis (NASH/MASH).

Use cases: Weight Management, Metabolic Health

Cotadutide — Phase I–II Clinical Trials

Evidence: C | Status: Phase II completed for T2D, obesity, and NASH/MASH. Development status uncertain; AstraZeneca has not advanced to Phase III.

Cotadutide (MEDI0382) is a dual GLP-1/glucagon receptor agonist developed by AstraZeneca (originally MedImmune). It is a once-daily injectable peptide designed to combine GLP-1 receptor-mediated glucose lowering and appetite suppression with...

Use cases: Metabolic Health, Weight Management

Shop Research Peptides

Retatrutide 20mg
In Stock

Retatrutide 20mg

20mg

$99 USD
BPC-157 5mg
In Stock

BPC-157 5mg

5mg

$34 USD
Ipamorelin 10mg
In Stock

Ipamorelin 10mg

10mg

$49 USD
Semaglutide 10mg
In Stock

Semaglutide 10mg

10mg

$49 USD
TB-500 5mg
In Stock

TB-500 5mg

5mg

$29 USD
Retatrutide 10mg
In Stock

Retatrutide 10mg

10mg

$64 USD
GHK-Cu 50mg
In Stock

GHK-Cu 50mg

50mg

$24 USD
Sermorelin 5mg
In Stock

Sermorelin 5mg

5mg

$34 USD
Tesamorelin 10mg
In Stock

Tesamorelin 10mg

10mg

$64 USD

Quality Documentation

Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.

Product cards on this page link to current catalog entries and available quality documentation.

Follow Research Updates

Get new research pages, product updates, tool releases, and quality resources from Volta.

Subscribe

Frequently Asked Questions

Related Research

Research Use Only. The information on this page is compiled from published research literature and is provided for educational purposes only. It does not constitute medical advice. All compounds referenced are intended for in vitro research use by qualified laboratories and institutions.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.